Clinical trial Recruiting at 2 sites Interventional Ages 18 to 85

Multivessel Hybrid Revascularization for Three-Vessel CAD vs Conventional Off-Pump CABG

Official title: MICRA-HYBRID Trial: A Randomized Controlled Trial of 'Multivessel Minimally Invasive Coronary Bypass Grafting as HYBRID Revascularization Versus Conventional Off-Pump Coronary Artery Bypass Grafting'

Run by Catharina Ziekenhuis Eindhoven · NCT07314138 · Data updated 2026-11-12

This trial tests whether a minimally invasive multivessel hybrid revascularization (LAD and circumflex grafted via a small thoracotomy plus PCI for the RCA) is better than traditional off-pump CABG done through sternotomy in people with three-vessel coronary disease.

Quick facts

Study typeInterventional
Ages18 Years to 85 Years
SexAll
Enrollment250 (estimated)
SponsorCatharina Ziekenhuis Eindhoven
Academic / other
Locations2 sites (Leuven, Vlaams Brabant and 1 other locations)
StatusRecruiting
StartedAugust 25, 2026
Main results expectedMay 1, 2029
Study endsMay 1, 2034
Registry record updatedAugust 27, 2026
Trial IDNCT07314138 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with three-vessel coronary disease eligible for complete revascularization, suitable for either multivessel-HCR or OPCAB.

Probably not a fit

Patients who do not meet inclusion criteria or have high-risk features that necessitate alternative strategies may not benefit from the hybrid approach.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multicenter randomized trial enrolling patients with three-vessel coronary disease to compare multivessel hybrid coronary revascularization (MICS-based arterial grafting to the LAD and LCx, plus PCI to the RCA) against conventional off-pump CABG via median sternotomy. The primary endpoint is a 30-day Textbook Outcome, a composite of death, myocardial infarction, stroke, re-exploration for bleeding, and other major complications. The study aims to determine if the hybrid approach improves perioperative recovery and long-term cardiovascular outcomes while reducing surgical trauma. Enrollment targets 250 participants across participating centers. Outcomes will inform whether multivessel-HCR can be a preferred revascularization strategy for complex three-vessel disease.

Why it matters

Potential benefit: If successful, patients could experience shorter recovery, fewer complications, and comparable or better long-term heart outcomes with a less invasive approach.

How similar studies have gone: Prior studies suggest favorable short-term recovery with minimally invasive strategies, but multivessel-HCR in this exact configuration is being evaluated for its added value.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with three-vessel disease (either angiographic stenoses \>70% or a fractional flow reserve value ≤0.80)
* Left main diameter stenosis ≥50% or a left main intravascular ultrasound minimal luminal area of ≤4.5 mm2 or fractional flow reserve value ≤0.80 combined with significant CAD of the right coronary artery

Exclusion Criteria:

A potential participant who meets any of the following criteria will be excluded from participation in this study:

* Age \< 18 or \> 85 years
* Chronic total occlusion of the RCA
* In-stent RCA restenosis
* RCA stenosis with high-risk clinical features requiring urgent PCI or surgical revasculari-zation.
* Reverse hybrid coronary revascularization, defined as PCI-RCA followed by surgical re-vascularization.
* Acute cardiac ischemia necessitating immediate intervention.
* EF \< 30 %
* eGFR \< 30 ml/min
* Indication for concomitant cardiac surgery (e.g. valve or arrhythmia surgery) or non-cardiac surgery
* Previous thoracic or cardiac surgery, mediastinal irradiation, significant trauma to the chest
* Preoperative severe end-organ dysfunction (dialysis, liver failure, respiratory failure) or cancer.
* Hemodynamically significant left subclavian stenosis
* Severe chest wall deformities
* History of pericarditis
* Body mass index \> 40 Kg/m2.

Where it's running

  • University Hospitals Leuven
    Leuven, Vlaams Brabant, Belgium
    Recruiting
  • Catharina Hospital Eindhoven
    Eindhoven, Eindhoven, Netherlands
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.